Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.
Clinical trial NCT01394796 · COMPLETED
Trial details
- NCT number
- NCT01394796
- Sponsor
- Parc de Salut Mar
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2010-05-01
- Primary completion
- 2011-02-01
- Enrollment
- 31
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.